Muscarinic acetylcholine receptor M2
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Muscarinic acetylcholine receptor M2 as ChEMBL target CHEMBL309, mapped to UniProt P10980. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Muscarinic acetylcholine receptor M2 matters
Muscarinic acetylcholine receptor M2 is reviewed as Muscarinic acetylcholine receptor M2 (UniProt P10980); the current evidence base includes 22 approved drugs, 692 compounds, and 178 assays, with lead potency reaching pChEMBL 10.6.
Muscarinic acetylcholine receptor M2 Sequence length is 466 aa.
Review this target as Muscarinic acetylcholine receptor M2, mapped to UniProt P10980. Sequence length is 466 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 22 approved drugs, 692 compounds, and 178 assays for this target. The dominant activity type is KI. CHEMBL3298595 is the current potency anchor at pChEMBL 10.6.
Use CHEMBL3298595 as the tractability anchor when discussing potency (pChEMBL 10.6).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Muscarinic acetylcholine receptor M2 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P10980, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3298595
|
10.6 | Ki | — |
|
|
No preferred name
CHEMBL558910
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL3298599
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL119294
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL21812
|
10.0 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
XANOMELINE
CHEMBL21536
|
2024 |
|
|
TIOTROPIUM BROMIDE
CHEMBL3545181
|
2004 |
|
|
DARIFENACIN
CHEMBL1346
|
2004 |
|
|
SOLIFENACIN
CHEMBL1734
|
2004 |
|
|
TOLTERODINE
CHEMBL1382
|
1998 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
METHACHOLINE
CHEMBL978
|
1986 |
|
|
SCOPOLAMINE
CHEMBL569713
|
1979 |
|
|
OXYBUTYNIN
CHEMBL1231
|
1975 |
|
|
CARBACHOL
CHEMBL14
|
1972 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
ATROPINE
CHEMBL517712
|
1960 |
|
|
BENZTROPINE
CHEMBL1201203
|
1954 |
|
|
DICYCLOMINE
CHEMBL1123
|
1950 |